| __timestamp | Celldex Therapeutics, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 4932500000 |
| Thursday, January 1, 2015 | 4011000 | 5037200000 |
| Friday, January 1, 2016 | 102026000 | 5654900000 |
| Sunday, January 1, 2017 | 96171000 | 6070200000 |
| Monday, January 1, 2018 | 66449000 | 4681700000 |
| Tuesday, January 1, 2019 | 42672000 | 4721200000 |
| Wednesday, January 1, 2020 | 42534000 | 5483300000 |
| Friday, January 1, 2021 | 3068000 | 7312800000 |
| Saturday, January 1, 2022 | 1400000 | 6629800000 |
| Sunday, January 1, 2023 | 3008000 | 7082200000 |
| Monday, January 1, 2024 | 8418299999 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Eli Lilly and Company, a stalwart in the industry, has consistently demonstrated robust cost management. From 2014 to 2023, their cost of revenue has shown a steady increase, peaking at approximately $7.3 billion in 2021, reflecting a 48% rise from 2014. This trend underscores their strategic investments in innovation and production efficiency.
Conversely, Celldex Therapeutics, Inc., a smaller player, presents a contrasting narrative. Their cost of revenue has fluctuated significantly, with a notable peak in 2016, followed by a sharp decline. By 2023, their costs had plummeted by over 97% from their 2014 high, highlighting the volatility and challenges faced by emerging biotech firms.
These trends offer a fascinating glimpse into the financial strategies and market positions of these two distinct entities.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Celldex Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Alkermes plc vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.